Drug Lobby Driving PBS Changes, Says Expert (Australia)
This article was originally published in PharmAsia News
Executive Summary
Australia's parliament is considering new amendments to the Pharmaceutical Benefits Scheme that will establish separate criteria for evaluating pricing of brand-name and generic drugs in Australia, and therefore affect Australian drug pricing. Australian National University expert Dr. Thomas Faunce says the amendments, if approved, will drive up brand-name drug costs. He notes that the proposed changes are backed by Australia's pharmaceutical lobby Medicines Australia. Faunce says the amendments would obviate current "reference pricing," which currently requires that new patented drugs first prove they are superior to existing products. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.